A 64‐year‐old male with ALK‐positive nonsmall cell lung carcinoma on oral therapywith alectinib presented with pleural effusion. ...Peripheral blood film displayed marked acanthocytes and spheroacanthocytes..Alectinib is a novel tyrosine kinase inhibitor approved for use in patients with nonsmall cell lung cancer. Alectinib is known to cause anemia but the striking acanthocytes and spheroacanthocytes have only been reported in a few case series. Spheroacanthocytes are commonly associated with end‐stage liver disease; however, hematopathologists should recognize alectinib as an alternate cause for acanthocytes and spheroacanthocytes on a peripheral blood film. READ ARTICLE
eJHaem DOI:10.1002/jha2.104
Authors: Michael Ashby, Michael Sze Yuan Low
